Drug Profile
Research programme: methioninase gene therapies - AntiCancer
Alternative Names: Adeno MET gene/selenomethionine; Geneceuticals; GFP-bacterial MET gene/selenomethionine; METgene-SeMET; rAd-MET/SeMETLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AntiCancer
- Class Antineoplastics; Gene therapies; Oxidants
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 22 Jun 2011 Research programme: methioninase gene therapies - AntiCancer is available for licensing as of 22 Jun 2011. http://www.anticancer.com
- 06 Apr 2011 Preclinical toxicology data in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011)